R&D | March 29, 2026
Rocket Pharma gets FDA nod for first pediatric gene therapy targeting severe LAD-I
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Doctors at the hospital highlighted that robotic-assisted surgery enhances precision through superior 3D visualisation and improved instrument flexibility
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
Subscribe To Our Newsletter & Stay Updated
